Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech Founder Ge Li Says Upcoming Merger With Charles River Is Part Of Globalization Of The Drive To Save Lives

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The chief executive officer of Shanghai-headquartered WuXi PharmaTech, Ge Li, said that a planned merger with Massachusetts-based contract research organization Charles River could help spark a "revolution" in early-stage drug research in China

You may also be interested in...



Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma

BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai

Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma

BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai

Charles River Abandons WuXi PharmaTech Just Days Before Crucial Shareholder Votes On Planned Merger

BEIJING - Like a prospective bride who has been jilted at the very last moment by a suitor, Shanghai's WuXi PharmaTech has been abandoned by the Massachusetts-headquartered Charles River Laboratories on the eve of the two contract research organizations' merger

Related Content

UsernamePublicRestriction

Register

SC074701

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel